JMP reiterates MedImmune at market perform

MedImmune, Inc. was reiterated by JMP Securities analyst Adam Cutler at market perform as the company's second-quarter financial results missed the analyst's estimate due to light Synagis sales. Total revenue of $66 million missed JMP's estimate of $91.6 million and the Street consensus of $83 million. MedImmune said new programs will boost product sales by increasing payor acceptance of Synagis and said it's on track to meet Synagis 2006 sales guidance. Shares of the Gaithersburg, Md.-based biotechnology company were down 2 cents, or 0.08%, at $25.44 on volume of 4,130,996 shares versus the three-month running average of 3,294,570 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.